Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

life sciences

- PMLiVE

Ipsen’s Iqirvo receives FDA approval to treat adults with primary biliary cholangitis

The rare cholestatic liver disease currently affects approximately 100,000 people in the US

- PMLiVE

Ipsen and Marengo expand oncology research partnership in deal worth $1.2bn

The new agreement centres around Marengo’s TriSTAR T-cell engager platform

- PMLiVE

Novo Nordisk Foundation, Wellcome and Gates Foundation collaborate to accelerate global health equity

The collaboration will support solutions to address the health impacts of climate change, infectious diseases and AMR

- PMLiVE

Ipsen and Skyhawk announce $1.8bn partnership to advance rare neurological disease therapies

The agreement gives Ipsen an option to receive exclusive global rights to two candidates

- PMLiVE

Ipsen announces launch of new UK headquarters in London life sciences community

The Paddington site will serve as one of the company’s three global hubs

- PMLiVE

Ipsen enters $900m licensing agreement for Sutro Biopharma’s ADC candidate

STRO-003 will be the first ADC candidate to be added to Ipsen’s portfolio

- PMLiVE

Indegene announces acquisition of Trilogy Writing & Consulting

The deal is aimed at increasing Indegene’s clinical and regulatory writing expertise for global market authorisation applications

- PMLiVE

Ipsen’s Cabometyx and BMS’ Opdivo recommended by NICE for advanced kidney cancer

The decision could benefit approximately 2,287 patients with renal cell carcinoma annually

- PMLiVE

ABPI sets out UK life sciences industry’s priorities for government’s budget

The ABPI highlights four key areas where the budget could boost UK life sciences

- PMLiVE

Ipsen’s Onivyde regimen granted FDA approval to treat pancreatic cancer

Around 60,000 people are diagnosed with pancreatic adenocarcinoma in the US every year

- PMLiVE

ABPI publishes manifesto for government to accelerate UK life sciences industry

The trade association has called on political parties to commit to three broad goals and requirements

- PMLiVE

Roche and Exelis/Ipsen’s drug combination shows promise in phase 3 prostate cancer study

Around 299,000 new cases of prostate cancer will be diagnosed in the US in 2024

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links